Thomas Pintar, MD
Nephrology · Boise, IDNPI 1952343352
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 22.9% of the total. That places this record below the midpoint for nephrology clinicians in ID, where the typical reported total is $347.
Across 11 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$38
- Otsuka America Pharmaceutical, Inc.$33
- Genentech USA, Inc.$32
- Vifor Pharma, Inc.$21
- Novo Nordisk$18
- Novartis$12
- plus $10 from 1 others
What the payments were for
- Food & beverage$15494%
- Education$106%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 1 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $32 |
| Vifor Pharma, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $18 |
| Novartis | 1 | $12 |
| Travere Therapeutics, Inc. | 3 | $10 |
How this compares
$164 in reported general payments places this provider in the 25th percentile of 30 nephrology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 143 | $154,430 |
| JardianceEmpagliflozin | 68 | $72,227 |
| EliquisApixaban | 31 | $23,563 |
| Sevelamer Carbonate | 88 | $21,830 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $15,887 |
| Cinacalcet Hcl | 23 | $10,798 |
| ProsolParenteral Amino Acid 20% No.1 | 47 | $7,241 |
| Potassium Chloride | 74 | $4,596 |
| Calcium Acetate | 45 | $3,166 |
| Bumetanide | 22 | $1,619 |
| Losartan Potassium | 169 | $1,369 |
| Allopurinol | 124 | $1,189 |
| Furosemide | 151 | $900 |
| Ondansetron OdtOndansetron | 19 | $739 |
| Torsemide | 33 | $696 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Boise
- Nicholas HuntBoise$256
- Micheal AdcoxBoise$221
- Arnold SilvaMeridian$626K
- Liang WuMeridian$386K
- Mary DittrichMeridian$7K
- Shaun JoshiHayden$5K
- Heidi JoistNampa$4K
- Naeem RahimChubbuck$696
- Kevin MitchellMeridian$679
- Ajith KumarLewiston$672
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.